Figure 1. Expression of human SIGLEC15 on CT26-hSIGLEC15 cells was confirmed by flow cytometry.
CT26-hSIGLEC15 cells and wild type CT26 cells were stained with species-specific anti-SIGLEC15 antibody. FACS analysis shows that human SIGLEC15 expression on CT26-hSIGLEC15 cells was detectable. Human SIGLEC15 expression of 18# and 28# clones were 52.65% and 93.15%.
Figure 2. In vivo tumor growth curves in humanized CT26-hSIGLEC15 syngeneic model.
BALB/c mice were subcutaneously injected CT26-hSIGLEC15 cells. Tumor growth was monitored by measuring tumor size from day 14 after subcutaneous implantation.
Figure 3. FACS analysis of SIGLEC15 expression on tumor cells derived from humanized CT26-hSIGLEC15 syngeneic model with species-specific anti-SIGLEC15 antibodies.
FACS analysis shows that human SIGLEC15 expression in human SIGLEC15 knock-in tumor were 48.61% (18# clone) and 60.48% (28# clone).
Please fill in the order form and we will contact you within 2 working days.
